Best Hospitals for Heart Valve Repair in Dubai, UAE

Heart valve repair surgery in India is estimated to cost between USD 6,000 and USD 12,000, depending on the complexity of the procedure (isolated posterior leaflet repair vs. complex bileaflet or combined valve and CABG surgery), the surgical approach (conventional sternotomy vs. minimally invasive right thoracotomy vs. robotic-assisted), the tier of the treating facility (NABH- or JCI-accredited hospital), and the surgeon's experience level. This cost typically includes surgeon and anesthesiologist fees, operative costs (cardiopulmonary bypass, disposables, annuloplasty ring or neo-chordal PTFE sutures), a 7–12 day hospital stay inclusive of 2–3 days in the cardiac ICU, standard post-operative medications during hospitalization, and standard nursing care. In the UAE (Dubai or Abu Dhabi), the equivalent procedure at JCI- and DHA-accredited facilities ranges from USD 15,000 to USD 28,000, reflecting premium hospital infrastructure, higher local operating costs, and luxury patient service standards. Both destinations are significantly more cost-effective than the United States, where an equivalent procedure may cost USD 80,000–150,000, or the United Kingdom (NHS private sector: USD 40,000–70,000). Costs for transcatheter edge-to-edge repair (MitraClip/PASCAL) in India range from USD 18,000–25,000 (driven by device cost) and USD 28,000–40,000 in the UAE. GAF Healthcare provides each patient with a fully itemized, personalized cost estimate before travel commitment.

Patients undergoing open heart valve repair surgery (via median sternotomy or minimally invasive right thoracotomy) should plan for a total in-country stay of 4 to 6 weeks before receiving formal medical clearance for an international long-haul flight. This timeline breaks down as follows: 7–12 days as an inpatient (including 2–3 days in the cardiac ICU), followed by 3–4 weeks of closely monitored post-discharge recovery in nearby accommodation. Before issuing fit-to-fly clearance, the treating cardiologist must confirm: complete sternal or thoracotomy wound healing without infection, no clinically significant pericardial effusion on echocardiography (which peaks at 2–4 weeks post-operatively), therapeutic and stable anticoagulation (if on warfarin) with no active INR lability, controlled or resolved post-operative atrial fibrillation, and adequate functional capacity (ability to walk 200–300 meters comfortably). For patients undergoing transcatheter procedures (MitraClip TEER or percutaneous mitral balloon commissurotomy), the recovery is substantially shorter—fit-to-fly clearance may be granted at 1–2 weeks post-procedure, subject to the same echocardiographic and hemodynamic criteria. When flying, patients should use graduated compression stockings (Class II, 15–20 mmHg) and, in high-risk cases, a prophylactic single dose of low-molecular-weight heparin (LMWH such as enoxaparin 40mg SC) 2–4 hours before boarding for DVT prevention. Patients should request bulkhead or aisle seating to allow regular ambulation during the flight. A comprehensive medical summary letter for the airline and destination healthcare system is provided by GAF Healthcare at discharge.

Heart valve repair surgery achieves excellent outcomes when performed at high-volume, experienced cardiac centers—the very centers to which GAF Healthcare refers its international patients. The procedural success rate (defined as achieving ≤1+ residual regurgitation on intraoperative TEE assessment, with the patient separated from cardiopulmonary bypass without the need for conversion to valve replacement) is 95–98% for degenerative mitral valve disease (the most common and most repairable etiology) in the hands of experienced mitral valve surgeons performing more than 50 mitral repairs annually. Long-term durability is equally impressive: freedom from reoperation at 10 years is 85–90% for posterior leaflet repairs and approximately 75–85% for anterior or bileaflet repairs at specialized centers. For rheumatic mitral disease, repair durability is lower (freedom from reoperation 60–70% at 10 years) due to the progressive fibrotic nature of the disease, which is why valve replacement may ultimately be preferred in certain rheumatic presentations. Operative (30-day) mortality for elective isolated mitral valve repair is 0.5–1.5% at high-volume centers (consistent with STS and EuroSCORE II predictions for low-to-moderate risk patients). Aortic valve repair (David/Yacoub procedures) achieves freedom from reoperation of 85–90% at 10–15 years in experienced aortic valve centers. Transcatheter edge-to-edge repair (MitraClip/PASCAL) achieves procedural success in 90–95% of anatomically suitable patients, with significant sustained reduction in MR grade and improvement in NYHA functional class and quality of life at 2-year follow-up (COAPT and EVEREST II trial data), though residual moderate MR rates are higher than surgical repair. Patients should note that success rates are strongly center- and surgeon-dependent; GAF Healthcare exclusively partners with facilities and surgeons whose published outcomes meet or exceed these international benchmarks.